Immunotherapy of renal cell carcinoma: Current state of the problem and promising areas of research

Cover Page

Cite item

Full Text

Abstract

This review considers current variants of immunotherapy in patients with disseminated renal cell carcinoma. Data from experimental studies concerning defects in immunocompetent cells and mechanisms that block the normal immune response in patients with tumors are presented. Data of completed clinical trials of blockers of co-inhibiting molecules and cytokines in patients with renal cell carcinoma are analyzed.

About the authors

Oleg E. Molchanov

Russian Research Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: molchanovo@mail.ru

Doctor of Medical Sciences, Head (Department of Fundamental Medicine), Head (Group of Molecular Biological Prediction and Individualization of Treatment)

Russian Federation, Saint Petersburg

References

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015;136(5):359-386. doi: 10.1002/ijc.29210.
  2. Abe H, Kami T. Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol. 2013;20(10):944-955. doi: 10.1111/iju.12187.
  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013.
  4. Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res. 2014;2(12):1132-1141. doi: 10.1158/2326-6066.CIR-14-0193.
  5. Kulbe H, Levinson N, Balkwill F, Wilson JL. The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol. 2004;48(5-6):489-496. doi: 10.1387/ijdb.041814hk.
  6. Rundhaug J. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res. 2003;9(3):551-554.
  7. Egeblad M, Werb Z. New functions of metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174. doi: 10.1038/nrc745.
  8. Folgueras A, Pendas A, Sanchez L, Lopez-Otin T. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 2004;48(5-6):411-424. doi: 10.1387/ijdb.041811af.
  9. Hynes R. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8(9):918-921. doi: 10.1038/nm0902-918.
  10. Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17(3):155-167. doi: 10.2165/00063030-200317030-00002.
  11. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-555. doi: 10.1016/s1471-4906(02)02302-5.
  12. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):155-166. doi: 10.1172/jci31422.
  13. Lamagna C, Aurrand-Lions M, Imhof B. Dual role of macrophages in tumor growth and angiogenesis. J Leuc Biol. 2006;80(4):705-13. doi: 10.1189/jlb.1105656.
  14. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157(2):411-421. doi: 10.1016/s0002-9440(10)64554-3.
  15. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived supressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leuc Biol. 2008;83(5):1136-1144. doi: 10.1189/jlb.0907611.
  16. Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid cells in cancer immunity. Immunology. 2007;121(2):149-157. doi: 10.1111/j.1365-2567.2007.02579.x.
  17. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
  18. Wolf A, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606-612.
  19. Lu B, Finn O. T-cell death and cancer immune tolerance. Cell Death Differ. 2007;15(1):70-79. doi: 10.1038/sj.cdd.4402274.
  20. Arnold R, Brenner D, Becker M, et al. How T lymphocytes switch between life and death. Eur J Immunol. 2006;36(7):1654-1658. doi: 10.1002/eji.200636197.
  21. Heath WR, Kurts C, Miller J, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med. 1998;187(10):1549-1553. doi: 10.1084/jem.187.10.1549.
  22. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol. 2004;16(1):21-25. doi: 10.1016/j.coi.2003.11.007.
  23. Watts TH. TNF/TNFR family members in costimulation of T cell response. Annu Rev Immunol. 2005;23(1):23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
  24. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol. 2003;3(12):939-951. doi: 10.1038/nri1248.
  25. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23(1): 515-548. doi: 10.1146/annurev.immunol.23.021704.115611.
  26. Davis MM. A new trigger for T cells. Cell. 2002;110(3):285-287. doi: 10.1016/s0092-8674(02)00865-6.
  27. Inman BA, Frigola X, Dong H, Kwon E. Costimulation, coinhibition and cancer. Curr Cancer Drug Targ. 2007;7(1):15-30. doi: 10.2174/156800907780006878.
  28. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97(6):439-447. doi: 10.1111/j.1349-7006.2006.00197.x.
  29. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47-62. doi: 10.1186/s13045-016-0277-y.
  30. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-6. doi: 10.1126/science.271.5256.1734.
  31. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998;188(1):205-210. doi: 10.1084/jem.188.1.205.
  32. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712-4717. doi: 10.1073/pnas.0830997100.
  33. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;(2794):450-461. doi: 10.1016/j.ccell.2015.03.001.
  34. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526. doi: 10.1056/nejmoa1104621.
  35. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standart-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616-622. doi: 10.1200/jco.2012.44.6112.
  36. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-5074. doi: 10.1158/1078-0432.ccr-13-3271.
  37. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883-895. doi: 10.1084/jem.20051776.
  38. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665.
  39. McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from phase Ia study. J Clin Oncol. 2016;34(8):833-842. doi: 10.1200/jco.2015.63.7421.
  40. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830. doi: 10.1097/cji.0b013e318156e47e.
  41. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. doi: 10.1056/NEJMoa1200694.
  42. Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016;37(7):462-476. doi: 10.1016/j.it.2016.04.010.
  43. Galuzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4(11):895-902. doi: 10.1158/2326-6066.CIR-16-0197.
  44. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007-1008.
  45. Brisslert M, Bokarewa M, Larsson P, et al. Phenotypic and functional characterization of human CD25+ B cells. Immunology. 2006;117(4):548-557. doi: 10.1111/j.1365-2567.2006.02331.x.
  46. Kronin V, Vremec D, Shortman K. Dose the IL-2 receptor alpha chain induced on dendritic cells has a biological function? Int Immunol. 1998;10(2):237-240.
  47. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptor on lymphocytes and endothelial cells. Proc Natl Acad Sci USA. 2010;107(26):11906-11911. doi: 10.1073/pnas.1002569107.
  48. Malek TR. The biology of Interleukin-2. Annu Rev Immunol. 2008;26:453-479. doi: 10.1146/annurev.immunol.26.021607.090357.
  49. Rosenberg SA, Lotze MT, Muul LM, et al. Observations of the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485-1492. doi: 10.1056/NEJM198512053132327.
  50. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451-5458. doi: 10.4049/jimmunol.1490019.
  51. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997-2005. doi: 10.1200/JCO.2005.03.9594.
  52. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-841. doi: 10.1200/JCO.2005.05.179.
  53. Kaufman HL. Cancer immunotherapy with interleukin-2 - The PROCLAIMSM Registry. Oncol Hematol Rev. 2016;12(2):77-79. doi: 10.17925/ohr.2016.12.02.77.
  54. Clark J, McDermott DF, Dutcher JP, et al. Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint from PROCLAIM registry. J Clin Oncol. 2016;34(15 Suppl):4548. doi: 10.1200/jco.2016.34.15_suppl.4548.
  55. Молчанов О.Е. Современные прогностические системы в оценке эффективности системной химиоиммунотерапии почечно-клеточного рака с использованием рекомбинантного интерлейкина-2 // Вестник Санкт-Петербургского университета. - 2013. - Серия 11. - Вып. 2. - С. 141-148. [Molchanov OE. Current prognostic models in the estimation of the effectiveness of systemic chemoimmunotherapy with interleukin-2 in patients with renal cell carcinoma. Vestnik St. Petersburg University. 2013; Seriya 11 (Issue 2):141-147. (In Russ.)]
  56. Молчанов О.Е., Школьник М.И. Прогностическое значение иммунологических показателей у больных с опухолями мочеполовой системы // Медицина и образование в Сибири. - 2014. - № 6. [Molchanov OE, Shkol’nik MI. Prognosticheskoe znachenie immunologicheskih pokazatelej u bol’nyh s opuholjami mochepolovoj sistemy. Medicina i obrazovanie v Sibiri. 2014;(6). (In Russ.)] Доступно по: http://www.ngmu.ru/cozo/mos/article/text_full.php?id=1594. Ссылка активна на 15.09.2018.
  57. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(9):2859-2867. doi: 10.1200/jco.1999.17.9.2859.
  58. Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008;57(8):1115-1124. doi: 10.1007/s00262-007-0441-x.
  59. Молчанов О.Е., Гранов А.М. Способ лечения диссеминированного почечно-клеточного рака / Патент 2409382. Российская Федерация. - № 2009129923/15. Заявлено 5.08.2009; опубликовано 20.01.2011. [Molchanov OE, Granov AM. Sposob lechenija disseminirovannogo pochechno-kletochnogo raka / Patent 2409382. Russian Federation. No 2009129923/15. Stated 5.08.2009; published 20.01.2011. (In Russ.)] Доступно по: http://www.freepatent.ru/images/patents/51/2409382/patent-2409382.pdf. Ссылка активна на 15.09.2018.
  60. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Haematol Oncol. 2016;9(1):47-62. doi: 10.1186/s13045-016-0277-y.
  61. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541-3544. doi: 10.1200/jco.2015.61.6870.

Copyright (c) 2018 Molchanov O.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies